Charles River Q1 revenue falls 2.7% to $984.2 million; raises 2025 guidance
Charles River Laboratories reported first-quarter 2025 revenue of $984.2 million, down 2.7% from $1,011.6 million a year earlier, with GAAP diluted earnings per share of $0.50 versus $1.30. Non-GAAP diluted EPS rose 3.1% to $2.34, and the company raised its 2025 non-GAAP EPS guidance to $9.30 to $9.80 from $9.10 to $9.60, which matters to shareholders because revenue and GAAP profit declined while the outlook moved higher.
Key points
- Q1 2025 revenue was $984.2 million, down 2.7% from $1,011.6 million; organic revenue fell 1.8%.
- GAAP diluted EPS was $0.50 versus $1.30 in Q1 2024; non-GAAP diluted EPS was $2.34 versus $2.27.
- 2025 non-GAAP EPS guidance raised to $9.30 to $9.80 from $9.10 to $9.60; reported revenue guidance is now (5.5)% to (3.5)%.
- The company repurchased $350 million of common stock in Q1 and had $549.3 million remaining on its $1.0 billion authorization as of March 29, 2025.
The filing
Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.